Because of its critical role in these pathways, TAK1 has emerged as a potential therapeutic target for the treatment of inflammatory-mediated diseases like RA, ankylosing spondylitis, and inflammatory bowel disease [17–19]. This evidence concerns the gene MAP3K7 and rheumatoid arthritis.